The US Food and Drug Administration (FDA) has approved Theravance Biopharma's revefenacin for the maintenance treatment of chronic obstructive pulmonary disease.A long-acting muscarinic antagonist (LAMA), revefenacin is administered once daily 175 mcg vial (3 mL) via a standard jet nebulizer as an inhalation solution. In a year-long phase 3 clinical trial, over 1,000 patients with COPD demonstrated positive results with revefenacin treatment. Specifically, patients reported general, positive toleration with no new safety issues.The randomized, active-controlled parallel group trial included 2 different revefenacin doses: 88 mcg or 175 mcg, inhaled via a nebulizer once daily.
The drug's fixed-dosage safety and tolerability were tested over 52 weeks versus standard-of-care tiotropium, with the revefenacin participants comprising half of the study's patient pool. Other therapies, such as…
